Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Benzinga

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

Benzinga

Covid vaccine booster to be made available to more people in coming weeks

There are several ways you can book an appointments for yours

Dublin Live

From analysis to the latest developments in health,
read the most diverse news in one place.

A vaccine for Lyme disease is in its final clinical trial

There isn't currently a Lyme disease vaccine on the U.S. market. Researchers are hoping to change that.

WEKU

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Pfizer's Perth employees strike over pay

Pharmaceutical giant Pfizer is facing calls to improve its pay offer to manufacturing employees in Perth, who have walked off the job.

AAP

Trial seeks to develop first Lyme disease vaccine in 2 decades

The only Lyme disease vaccine previously marketed in the U.S. was discontinued in 2002.

Axios

Read news from The Economist, FT, and more,
with one subscription

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

Benzinga

Major test of first possible Lyme vaccine in 20 years begins

Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years

The Independent UK

Stock Market Rally Fades; These Energy, Health Care Stocks Break Out

Major indexes jumped at the week's opening, they pared most gains.

Investors Business Daily

Stock Market Gains On Tax, Climate, Health Care Bill; 6 Breakouts Amid Mixed Week Of Earnings

The stock market gained on tax, climate health care bill. The latest week or earnings arrived with lackluster results.

Investors Business Daily

Why Pfizer's $5.4 Billion GBT Takeover Is 'Mutually Beneficial'

Pfizer inked a $5.4 billion deal Monday to buy Global Blood Therapeutics, confirming rumors that sent GBT stock skyrocketing last week.

Investors Business Daily

BioNTech reports strong first half, expects demand to grow

BioNTech, which teamed with Pfizer to develop the first widely used COVID-19 vaccine, has reported higher revenue and net profit in the first half of the year

The Independent UK

Benzinga Before The Bell: Elon Musk Confirms Tesla AI Day Part 2, Dogecoin Scam, BioNTech Q2 Earnings Shocker And Other Top Financial Stories Monday, August 8

CNBC Celsius Withdraws Motion To Rehire CFO

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Reuters

Climate change puts Lyme disease in focus for France's Valneva after COVID blow

With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot.

Investors Business Daily

Stock Market Ends Upbeat Week With Mixed Results On Hot Job Numbers

The stock market traded mixed on Friday on hot job numbers, closing out the week with gains. AMC popped on earnings beat.

Investors Business Daily

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion

Rumors that Pfizer is in "advanced talks" to acquire Global Blood Therapeutics for about $5 billion sent GBT stock flying Friday.

Investors Business Daily

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug

Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy drug to gain traction.

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Over 1 million courses of Paxlovid prescribed in one month for first time

There were 1.26 million courses dispensed last month, a 37% increase when compared to June numbers.

Benzinga

Check Out What Whales Are Doing With PFE

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The Independent UK

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Conversation

Why the Jan. 6 hearings should be making corporations nervous

The world is watching the Jan. 6 hearings in the United States in dismay and contemplating the possible end of the American democratic experiment.

USAFacts

Who is eligible for the second COVID-19 booster?

21.2 million Americans received their second booster by the end of July.

Salon

Biden suffers a Paxlovid "rebound"

After taking Paxlovid, Biden tested negative for several days, then positive. He's not the only one

The Conversation

COVID: antiviral drugs are a vital weapon – but misusing them could backfire

The “living with COVID” strategy being pursued by many countries relies heavily on two key pillars. First, that vaccines continue to protect most people from severe disease. And second, that where they don’t, people will receive antiviral treatments. But are the antivirals currently available sufficiently effective, accessible and durable?

1 … 38 39 40 41

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.